Novartis Oncology is conducting the ATTRACT clinical research program for patients with advanced non-small cell lung cancer (NSCLC). ATTRACT stands for Antivascular Targeted Therapy: Researching ASA404 in Cancer Treatment. This clinical trial is testing the effectiveness and safety of ASA404 in combination with paclitaxel and carboplatin, 2 chemotherapy drugs that are used to treat non-small cell lung cancer (NSCLC). In order to participate in this study, you must be diagnosed with advanced NSCLC that has not yet been treated, and you must be an adult 18 years of age or older. To learn more about this research and to see if you may qualify to participate, click on the link below.